Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?

Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?

Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders. This study aimed to quantify the % of B cells following RTX therapy in patients with primary CNS demyelinating disorde...

Full description

Saved in:
Bibliographic Details
Main Authors: Sayan Chatterjee, Peyalee Sarkar, Mitali Chatterjee, Biman Kanti Ray
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-01-01
Series:Annals of Medical Science and Research
Subjects:
adrs of rituximab
cd20
primary cns demyelinating disorders
Online Access:https://journals.lww.com/10.4103/amsr.amsr_36_23
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items